TY - JOUR T1 - Activating and Resistance Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene and Non-Small Cell Lung Cancer: A Clinical Reality JO - Archivos de Bronconeumología T2 - AU - Taus,Álvaro AU - Vollmer,Iván AU - Arriola,Edurne SN - 15792129 M3 - 10.1016/S1579-2129(11)70021-0 DO - 10.1016/S1579-2129(11)70021-0 UR - https://www.archbronconeumol.org/en-activating-resistance-mutations-epidermal-growth-articulo-S1579212911700210 AB - In non-small cell lung cancer, EGFR gene mutations identify a patient sub-population with different clinical characteristics and treatment responses than those who do not present these mutations. There are mutations that lead to increased sensitivity to EGFR-targeted therapy, as well as mutations that result in resistance. The determination of EGFR mutations involves a change in the therapeutic approach to lung cancer patients in current clinical practice. In this article we present a case of a patient suffering from a metastatic lung adenocarcinoma with an activating mutation on diagnosis, initially responding to treatment with erlotinib, who subsequently developed a secondary resistance due to acquiring the T790M mutation in exon 20 of the EGFR gene. ER -